What insurance policy changes affect HCPCS J2786?

There are 12 tracked policy changes affecting HCPCS J2786, including updates from BCBS Tennessee, Aetna, Florida Blue. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for HCPCS J2786?

Payers that have issued tracked updates for HCPCS J2786 include: BCBS Tennessee, Aetna, Florida Blue, Anthem BCBS, Humana, Texas Medicaid.

How do I get notified when HCPCS J2786 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to HCPCS J2786. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for HCPCS J2786?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

J2786 Insurance Policy Changes

HCPCS J2786 is officially defined as "Injection, reslizumab, 1 mg." HCPCS J2786 is referenced in 12 tracked payer policy changes from BCBS Tennessee, Aetna, and 4 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J2786 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Medium impact
Reslizumab (Cinqair®)
BCBS Tennessee·Effective Dec 1, 2026
BlueCross BlueShield of Tennessee is implementing a new coverage policy for Reslizumab (Cinqair®) for severe eosinophilic asthma in adults 18+. The policy establishes prior authorization requirements, clinical criteria (eosinophil count ≥400 cells/mcL or systemic corticosteroid dependence plus uncontrolled asthma), prescriber specialty restrictions (allergist/immunologist or pulmonologist only), and a dosing limit of 3mg/kg IV every 4 weeks. Initial authorizations are granted for 6 months, with continuation authorizations for 12 months if asthma control improves.
High impact
Reslizumab (Cinqair) (CPB 0907, reviewed 2026-08-10)
Aetna·Effective Aug 10, 2026
Aetna updated its reslizumab (Cinqair) coverage policy for severe asthma treatment, effective immediately. The policy requires precertification for all commercial plans, restricts prescribing to allergists/immunologists or pulmonologists, and mandates specific clinical criteria including baseline eosinophil counts ≥400 cells/mcL or oral corticosteroid dependence, plus documented uncontrolled asthma despite high-dose ICS and additional controller therapy. Billing teams must implement prior authorization workflows and ensure claims include appropriate documentation before submission.
High impact
Tezepelumab-ekko (Tezspire) (CPB 1003, reviewed 2026-08-06)
Aetna·Effective Aug 6, 2026
Aetna has issued a NEW medical policy (CPB 1003, effective 2026-08-06) establishing coverage criteria for Tezepelumab-ekko (Tezspire) for severe asthma and chronic rhinosinusitis with nasal polyps in members 12+. The policy requires precertification for all members, mandates trial of lower-cost biologics first (when available), and restricts prescribing to allergists/immunologists, pulmonologists, or otolaryngologists. Billing teams must immediately implement prior authorization workflows and update coding systems.
High impact
New Drug Waste Reduction Guideline
Florida Blue·Effective Jun 1, 2026
Florida Blue is implementing a new Drug Waste Reduction Guideline effective June 1, 2026, requiring providers to use optimized doses that align with efficient vial combinations for specific injectable medications. The policy affects prior authorization processes and mandates dose optimization (including rounding down up to 10% when clinically appropriate) to reduce medication waste.
High impact
[New York] Specialty pharmacy updates, March 2026
Anthem BCBS·Effective Jun 1, 2026
Anthem is implementing new prior authorization, quantity limit, and step therapy requirements for 8 specialty pharmacy drugs effective June 1, 2026. Billing teams must update systems to require prior authorization for non-oncology specialty drugs managed by Anthem and oncology drugs managed by Carelon, and enforce quantity limits and step therapy edits on specified medications. Patients currently receiving these medications without prior auth may face coverage changes.
High impact
[Ohio] Specialty pharmacy updates, March 2026
Anthem BCBS·Effective Jun 1, 2026
Anthem is implementing new prior authorization requirements, quantity limits, and step therapy restrictions for 8 specialty pharmacy drugs effective June 1, 2026. Billing teams must obtain prior authorization for these medications before service dates and include NDC codes on claims to expedite processing. Patients currently receiving these drugs without authorization will require new prior auth requests going forward.
High impact
[Virginia] Specialty pharmacy updates, March 2026
Anthem BCBS·Effective Jun 1, 2026
Anthem Blue Cross Blue Shield (Virginia) is implementing new prior authorization, quantity limit, and step therapy requirements for 8 specialty pharmacy drugs effective June 1, 2026. Patients currently receiving these medications without prior authorization will require PA requests going forward. Billing teams must identify these drugs by NDC code and Clinical Criteria document number to route claims appropriately.
High impact
[Georgia] Specialty pharmacy updates, March 2026
Anthem BCBS·Effective Jun 1, 2026
Effective June 1, 2026, Anthem Blue Cross Blue Shield (Georgia) is implementing new prior authorization requirements, quantity limits, and step therapy protocols for 8 specialty pharmacy medications. Billing teams must begin requesting prior authorization for these drugs on all dates of service on or after June 1, 2026, and include NDC codes on claims to expedite processing. Oncology-use prior authorizations will be managed by Carelon Medical Benefits Management rather than Anthem's standard review team.
High impact
Medicare Part B Step Therapy May Updates
Florida Blue·Effective May 15, 2026
Florida Blue Medicare updated its Part B Step Therapy program effective May 15, 2026, adding new non-preferred drugs and changing preferred status for medications in Asthma, Cancer, and Hemophilia categories. Providers must try preferred alternatives before prescribing non-preferred drugs or face coverage denials.
High impact
Asthma Interleukin Inhibitors (Cinqair®, Nucala™, Fasenra®) (Revised)
Humana·Effective Jan 1, 2026
This is a revised Medicare Advantage prior authorization policy for asthma interleukin inhibitors (Cinqair, Nucala, Fasenra) effective January 1, 2026, with updates as of July 22, 2026. The policy establishes specific clinical criteria for coverage across five indications: severe eosinophilic asthma, EGPA, HES, chronic rhinosinusitis with nasal polyposis, and eosinophilic COPD. Billing teams must verify all prior authorization requirements before dispensing these specialty medications.
High impact
Benralizumab (Fasenra) (CPB 0925, reviewed 2025-12-23)
Aetna·Effective Dec 23, 2025
Aetna updated its Clinical Policy Bulletin (CPB 0925) for Benralizumab (Fasenra) effective December 23, 2025. This policy establishes coverage criteria for asthma and eosinophilic granulomatosis with polyangiitis (EGPA) with mandatory precertification requirements, specialty prescriber restrictions (allergist/immunologist or pulmonologist for asthma), and specific clinical thresholds including eosinophil counts and prior biologic drug history. Billing teams must implement prior authorization workflows immediately and ensure claims include required clinical documentation.
Medium impact
Prior Authorization Required for Depemokimab-ulaa (Exdensur)
Texas Medicaid·Effective Sep 1, 2026
Effective September 1, 2026, prior authorization is now required for depemokimab-ulaa (Exdensur), a subcutaneous injection for severe eosinophilic asthma in patients 12+. The billing team must obtain SMPA approval before claims are submitted, and must ensure claims do not combine J2361 with certain other monoclonal antibody codes (J0517, J2182, J2356, J2786) on the same date of service.

All billing codes J3590 99213 99214 99212 99202 99203

Get alerts for changes like this

Save a search and receive a daily digest whenever a new policy change matches your filters.

Create a free alert

Reslizumab (Cinqair®)

Reslizumab (Cinqair) (CPB 0907, reviewed 2026-08-10)

Tezepelumab-ekko (Tezspire) (CPB 1003, reviewed 2026-08-06)

New Drug Waste Reduction Guideline

[New York] Specialty pharmacy updates, March 2026

[Ohio] Specialty pharmacy updates, March 2026

[Virginia] Specialty pharmacy updates, March 2026

[Georgia] Specialty pharmacy updates, March 2026

Medicare Part B Step Therapy May Updates

Asthma Interleukin Inhibitors (Cinqair®, Nucala™, Fasenra®) (Revised)

Benralizumab (Fasenra) (CPB 0925, reviewed 2025-12-23)

Prior Authorization Required for Depemokimab-ulaa (Exdensur)